We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott's (ABT) Q4 Earnings Beat Estimates, Margins Down
Read MoreHide Full Article
Abbott Laboratories (ABT - Free Report) reported fourth-quarter 2022 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 14.4%. The adjusted figure however declined from the prior-year quarter’s levels by 22%.
The quarter’s adjustments include 44 cents of certain non-recurring items.
GAAP EPS came in at 59 cents, a 46.8% plunge year on year.
For the full year, adjusted EPS came in at $5.34, exceeding the Zacks Consensus Estimate and the year-ago figure by 2.5%?.
Fourth-quarter worldwide sales of $10.09 billion were down 12% year over year on a reported basis. The top line however exceeded the Zacks Consensus Estimate by 6.4%.
On an organic basis (excluding the impact of foreign exchange), sales declined 6.1% year over year in the reported quarter.
Worldwide sales for 2022 were $43.65 billion, up 1.3% from 2021 on a reported basis and 6.4% on an organic basis. The full-year top line exceeded the Zacks Consensus Estimate by 1.4%.
Quarter in Detail
Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics.
In the fourth quarter, Established Pharmaceuticals sales improved 1% on a reported basis (up 7.9% on an organic basis) to $1.22 billion. Organic sales in key emerging markets improved 10.3% year over year. According to Abbott, organic sales improvement was backed by strong growth in several geographies, including India, China, Brazil and Mexico, and across several therapeutic areas, including cardiometabolic, women's health and central nervous system/pain management.
Abbott Laboratories Price, Consensus and EPS Surprise
Medical Devices business sales were flat year over year on a reported basis (up 7.4% on an organic basis) at $3.75 billion. U.S. Sales growth was led by strong double-digit growth in Electrophysiology, Structural Heart and Diabetes Care. Internationally, sales growth was negatively impacted by intermittent COVID-19 lockdown restrictions in China as well as supply constraints in certain areas, most notably Electrophysiology and Diabetes Care.
Diabetes Care reported organic growth of 17.4% year over year, led by FreeStyle Libre, which contributed $1.1 billion of revenues in the reported quarter.Structural Heart sales rose 13% and Heart Failure sales improved 5.9% year over year organically. Meanwhile, the Vascular business recorded an organic sales decline of 1% in the quarter under review. Electrophysiology, Rhythm Management and Neuromodulation recorded organic growth of 7.3%, 1.5% and 0.9%, respectively, in the quarter under review.
Nutrition sales were down 11.1% year over year on a reported basis (down 5.7% on an organic basis) to $1.82 billion. Pediatric Nutrition sales registered an 11.8% slump on an organic basis. The downside was due to a manufacturing disruption during 2022 of certain infant formula products at Abbott's Sturgis, MI facility.
Adult Nutrition sales improved 0.5% organically. Per the company, Adult Nutrition sales benefited from improved sales performance of Abbott's complete and balanced nutrition brand, Ensure, globally.
Diagnostics sales were down 26.1% year over year on a reported basis (down 21.3% on an organic basis) to $3.31 billion. Core Laboratory Diagnostics sales were up 2.8% organically. Meanwhile, Molecular Diagnostics declined 44.7% on an organic basis. Rapid Diagnostics sales declined 31.6% on an organic basis, whereas Point of Care Diagnostics sales fell 1.2% organically.
Margins
Gross profit for the reported quarter fell 17.9% year over year to $5.49 billion. Gross margin contracted 396 basis points (bps) to 54.5%.
Selling, general and administrative expenses were down 2.5% year over year to $2.97 billion. Research and development expenses declined 4.9% year over year to $725 million.
The company reported an adjusted operating profit of $1.80 billion for the quarter under review, down 37.8% year over year. Adjusted operating margin, too, contracted 738 bps to 17.8%.
2023 Guidance
Abbott issued its 2023 EPS guidance.
Full-year adjusted earnings (excluding specified items of $1.25 per share) are expected to be in the range of $4.30 to $4.50. The current Zacks Consensus Estimate is pegged at $4.39.
Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits and COVID testing-related sales of around $2 billion.
Our Take
Abbott exited the fourth quarter of 2022 with better-than-expected earnings and revenues. However, the figures declined on a year-over-year basis. Total sales in the fourth quarter were negatively impacted by a year-over-year decline in COVID testing-related sales. Moreover, the decline in U.S. infant formula sales due to manufacturing disruptions dented the quarter’s sales further.
Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Cardinal Health (CAH - Free Report) will release fourth-quarter 2022 results on Feb 2.
Cardinal Health has a long-term expected earnings growth rate of 11.7%. Cardinal Health’s earnings yield of 6.87% compares favorably with the industry’s 4.34%.
McKesson Corporation (MCK - Free Report) will release third-quarter fiscal 2023 results on Feb 1.
MCK’s long-term historical earnings growth rate is estimated at 10.1%. MCK’s earnings yield of 6.49% compares favorably with the industry’s 4.34%.
Laboratory Corporation of America Holdings or LabCorp (LH - Free Report) will release fourth-quarter 2022 results on Feb 16.
LabCorp’s long-term historical earnings growth rate is estimated at 26.1%. LabCorp’s earnings yield of 7.02% compares favorably with the industry’s 4.34%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott's (ABT) Q4 Earnings Beat Estimates, Margins Down
Abbott Laboratories (ABT - Free Report) reported fourth-quarter 2022 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 14.4%. The adjusted figure however declined from the prior-year quarter’s levels by 22%.
The quarter’s adjustments include 44 cents of certain non-recurring items.
GAAP EPS came in at 59 cents, a 46.8% plunge year on year.
For the full year, adjusted EPS came in at $5.34, exceeding the Zacks Consensus Estimate and the year-ago figure by 2.5%?.
Fourth-quarter worldwide sales of $10.09 billion were down 12% year over year on a reported basis. The top line however exceeded the Zacks Consensus Estimate by 6.4%.
On an organic basis (excluding the impact of foreign exchange), sales declined 6.1% year over year in the reported quarter.
Worldwide sales for 2022 were $43.65 billion, up 1.3% from 2021 on a reported basis and 6.4% on an organic basis. The full-year top line exceeded the Zacks Consensus Estimate by 1.4%.
Quarter in Detail
Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics.
In the fourth quarter, Established Pharmaceuticals sales improved 1% on a reported basis (up 7.9% on an organic basis) to $1.22 billion. Organic sales in key emerging markets improved 10.3% year over year. According to Abbott, organic sales improvement was backed by strong growth in several geographies, including India, China, Brazil and Mexico, and across several therapeutic areas, including cardiometabolic, women's health and central nervous system/pain management.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote
Medical Devices business sales were flat year over year on a reported basis (up 7.4% on an organic basis) at $3.75 billion. U.S. Sales growth was led by strong double-digit growth in Electrophysiology, Structural Heart and Diabetes Care. Internationally, sales growth was negatively impacted by intermittent COVID-19 lockdown restrictions in China as well as supply constraints in certain areas, most notably Electrophysiology and Diabetes Care.
Diabetes Care reported organic growth of 17.4% year over year, led by FreeStyle Libre, which contributed $1.1 billion of revenues in the reported quarter.Structural Heart sales rose 13% and Heart Failure sales improved 5.9% year over year organically. Meanwhile, the Vascular business recorded an organic sales decline of 1% in the quarter under review. Electrophysiology, Rhythm Management and Neuromodulation recorded organic growth of 7.3%, 1.5% and 0.9%, respectively, in the quarter under review.
Nutrition sales were down 11.1% year over year on a reported basis (down 5.7% on an organic basis) to $1.82 billion. Pediatric Nutrition sales registered an 11.8% slump on an organic basis. The downside was due to a manufacturing disruption during 2022 of certain infant formula products at Abbott's Sturgis, MI facility.
Adult Nutrition sales improved 0.5% organically. Per the company, Adult Nutrition sales benefited from improved sales performance of Abbott's complete and balanced nutrition brand, Ensure, globally.
Diagnostics sales were down 26.1% year over year on a reported basis (down 21.3% on an organic basis) to $3.31 billion. Core Laboratory Diagnostics sales were up 2.8% organically. Meanwhile, Molecular Diagnostics declined 44.7% on an organic basis. Rapid Diagnostics sales declined 31.6% on an organic basis, whereas Point of Care Diagnostics sales fell 1.2% organically.
Margins
Gross profit for the reported quarter fell 17.9% year over year to $5.49 billion. Gross margin contracted 396 basis points (bps) to 54.5%.
Selling, general and administrative expenses were down 2.5% year over year to $2.97 billion. Research and development expenses declined 4.9% year over year to $725 million.
The company reported an adjusted operating profit of $1.80 billion for the quarter under review, down 37.8% year over year. Adjusted operating margin, too, contracted 738 bps to 17.8%.
2023 Guidance
Abbott issued its 2023 EPS guidance.
Full-year adjusted earnings (excluding specified items of $1.25 per share) are expected to be in the range of $4.30 to $4.50. The current Zacks Consensus Estimate is pegged at $4.39.
Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits and COVID testing-related sales of around $2 billion.
Our Take
Abbott exited the fourth quarter of 2022 with better-than-expected earnings and revenues. However, the figures declined on a year-over-year basis. Total sales in the fourth quarter were negatively impacted by a year-over-year decline in COVID testing-related sales. Moreover, the decline in U.S. infant formula sales due to manufacturing disruptions dented the quarter’s sales further.
Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Zacks Rank and Upcoming Releases
Abbott currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cardinal Health (CAH - Free Report) will release fourth-quarter 2022 results on Feb 2.
Cardinal Health has a long-term expected earnings growth rate of 11.7%. Cardinal Health’s earnings yield of 6.87% compares favorably with the industry’s 4.34%.
McKesson Corporation (MCK - Free Report) will release third-quarter fiscal 2023 results on Feb 1.
MCK’s long-term historical earnings growth rate is estimated at 10.1%. MCK’s earnings yield of 6.49% compares favorably with the industry’s 4.34%.
Laboratory Corporation of America Holdings or LabCorp (LH - Free Report) will release fourth-quarter 2022 results on Feb 16.
LabCorp’s long-term historical earnings growth rate is estimated at 26.1%. LabCorp’s earnings yield of 7.02% compares favorably with the industry’s 4.34%.